Can Orexigen Therapeutics Catch Up With Arena Pharmaceuticals and VIVUS?

Orexigen Therapeutics (NASDAQ: OREX  ) will release its quarterly report on Tuesday, and investors have gotten increasingly nervous in recent months about the drug company's future prospects. Although its Contrave obesity drug stands a good shot at gaining approval in the U.S. and Europe in the near future, it will have to get past two competing drugs: Qsymia from VIVUS (NASDAQ: VVUS  ) and Belviq from Arena Pharmaceuticals (NASDAQ: ARNA  ) . Does Contrave stand a chance?

Orexigen and its two main rivals all developed obesity drugs at roughly the same time, aiming to become the first treatments approved for the indication in years. All three of their drugs initially got rejected in late 2010 and early 2011, but the FDA required Orexigen to run another large clinical trial to address safety concerns, giving VIVUS and Arena the inside track to their eventual approval. Now, though, Orexigen is getting close to a point at which it can try for FDA approval again. Let's take an early look at what's been happening with Orexigen Therapeutics over the past quarter and what we're likely to see in its report.

Stats on Orexigen Therapeutics

Analyst EPS Estimate

($0.18)

Year-Ago EPS

($0.44)

Revenue Estimate

$890,000

Change From Year-Ago Revenue

3.9%

Earnings Beats in Past 4 Quarters

2

Source: Yahoo! Finance.

Will Orexigen finally start moving forward next year on earnings?
Analysts have become more positive about Orexigen's earnings prospects, cutting their loss estimates for the full 2014 year in half in recent months. The stock, though, has moved steadily lower, falling 31% since early August.

Given that Orexigen doesn't have any approved products on the market, earnings reports tend to focus on future expectations. In August, the company said that the American Medical Association's decision to classify obesity as a disease could become a door-opener for greater use of obesity drugs like Contrave. Orexigen also said it would submit Contrave for approval in Europe before the end of the year, with an FDA filing likely to come in a similar time frame.

In the meantime, though, both VIVUS and Arena Pharmaceuticals have struggled with their obesity drugs and are taking steps to try to bolster their sales. Arena recently expanded its marketing agreement with Japan's Eisai in order to spur further use of Belviq, which hasn't produced the sales that Arena's investors had hoped to see. VIVUS's Qsymia sales only added up to $11.1 million during the quarter, with the company having to lay off a sixth of its workers as a cost-cutting measure. Orexigen has already lined up Takeda Pharmaceuticals to sell Contrave in North America.

Despite the efforts of Arena and VIVUS, Orexigen has some advantages over both. Some analysts have argued that Contrave has advantages over both Belviq and Qsymia, with a more attractive mix of effectiveness and safety than either of its two rivals. If Orexigen can convince reluctant doctors to prescribe Contrave over the other two drugs, it could still end up being the winner.

In the Orexigen earnings report, watch to see how the company European approval plans go. With the potential of gaining early access to the European market, Contrave could get its biggest success across the Atlantic if Orexigen can work quickly.

Is fighting cancer more lucrative than fighting obesity?
Despite the obesity epidemic, cancer treatments still get huge amounts of attention, and your best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Click here to add Orexigen Therapeutics to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.


Read/Post Comments (4) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 10, 2013, at 5:41 PM, marp11 wrote:

    You boys should take a break..

    Arna won this fight

  • Report this Comment On November 10, 2013, at 5:46 PM, marp11 wrote:

    I imagine with the entire world as a customer and on completion.surname is the king.

    But I still want rs drivel to come back.

    Did you forget the 1.56 billion in milestones .?..

    Yes yes Eisai just throwing away billions......

    Try again

  • Report this Comment On November 10, 2013, at 6:15 PM, marp11 wrote:

    With spencer Mia And Adam Hiding

    MF has to work triple ot to pick up

    The bashing of belviq

    Guess eisai is just soooo dumb Putting up billions

    On a loser

    See ya

  • Report this Comment On November 10, 2013, at 6:17 PM, 1yossi1 wrote:

    Maybe "a more attractive mix of effectiveness and safety than either of its two rivals" BELVIQ and Qsymia, but NOT a more attractive mix of effectiveness and safety than Lorc/Phen combo!

    Lorc/Phen combo drug will "kill" both (Qsymia and Contrave)!

Add your comment.

DocumentId: 2720669, ~/Articles/ArticleHandler.aspx, 7/24/2014 2:27:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 3.48 0.18%
NASD 4,473.70 17.68 0.40%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

7/23/2014 3:59 PM
ARNA $4.88 Up +0.04 +0.83%
Arena Pharmaceutic… CAPS Rating: ***
OREX $5.34 Up +0.05 +0.95%
Orexigen Therapeut… CAPS Rating: **
VVUS $4.81 Up +0.06 +1.26%
VIVUS, Inc. CAPS Rating: **

Advertisement